- Home
- EPRX vs CHRS Comparison
EPRX vs CHRS Comparison
Compare EPRX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- CHRS
- Stock Information
- Founded
- EPRX 2011
- CHRS 2010
- Country
- EPRX Canada
- CHRS United States
- Employees
- EPRX N/A
- CHRS N/A
- Industry
- EPRX
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPRX
- CHRS Health Care
- Exchange
- EPRX NYSE
- CHRS Nasdaq
- Market Cap
- EPRX 137.7M
- CHRS 112.5M
- IPO Year
- EPRX N/A
- CHRS 2014
- Fundamental
- Price
- EPRX $3.94
- CHRS $0.76
- Analyst Decision
- EPRX Strong Buy
- CHRS Buy
- Analyst Count
- EPRX 1
- CHRS 3
- Target Price
- EPRX $9.00
- CHRS $4.68
- AVG Volume (30 Days)
- EPRX 17.5K
- CHRS 1.5M
- Earning Date
- EPRX 05-06-2025
- CHRS 05-12-2025
- Dividend Yield
- EPRX N/A
- CHRS N/A
- EPS Growth
- EPRX N/A
- CHRS N/A
- EPS
- EPRX N/A
- CHRS N/A
- Revenue
- EPRX N/A
- CHRS $272,251,000.00
- Revenue This Year
- EPRX N/A
- CHRS N/A
- Revenue Next Year
- EPRX N/A
- CHRS $19.78
- P/E Ratio
- EPRX N/A
- CHRS $1.83
- Revenue Growth
- EPRX N/A
- CHRS 19.87
- 52 Week Low
- EPRX $2.20
- CHRS $0.66
- 52 Week High
- EPRX $4.48
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- CHRS 39.42
- Support Level
- EPRX N/A
- CHRS $0.74
- Resistance Level
- EPRX N/A
- CHRS $0.82
- Average True Range (ATR)
- EPRX 0.00
- CHRS 0.06
- MACD
- EPRX 0.00
- CHRS -0.00
- Stochastic Oscillator
- EPRX 0.00
- CHRS 23.41
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.